MARKET

ACST

ACST

Acasti Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2070
+0.0065
+3.24%
After Hours: 0.2021 -0.0049 -2.37% 17:46 10/23 EDT
OPEN
0.2005
PREV CLOSE
0.2005
HIGH
0.2070
LOW
0.2001
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
3.080
52 WEEK LOW
0.1830
MARKET CAP
20.06M
P/E (TTM)
-0.6863
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Acasti Pharma Announces Review Process of Strategic Alternatives
LAVAL, Québec, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST) announces the Company has commenced a formal process to explore and
Benzinga · 09/29 11:03
Acasti announces initiation of strategic alternative process
Acasti Pharma (ACST) has commenced a formal process to explore and evaluate strategic alternatives to enhance shareholder value.The Company has engaged Oppenheimer as its financial advisor to assist in the
Seekingalpha · 09/29 10:59
Bank-backed stock exchange launches to rival Nasdaq, NYSE
A new exchange backed by Wall Street banks and asset management behemoth BlackRock ([[BLK]] -1.8%) started giving existing stock exchanges a run for their money today.Members Exchange, or MEMX, executed
Seekingalpha · 09/21 19:22
Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
LAVAL, Quebec, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has appointed seasoned financial executive Brian D. Ford as its Chief Financial Officer, effective September 14, 2020. Mr. Ford assumes the responsibilities
GlobeNewswire · 09/16 10:55
Acasti Announces Filing and Mailing of Information Circular and Change in Record Date
LAVAL, Quebec, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has filed and mailed the information circular and management proxy statement (the “Circular”) for its upcoming annual and special meeting of shareholders to
GlobeNewswire · 09/11 12:00
The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 11:25
Acasti Pharma Stock Loses a Wall Street Supporter
TipRanks · 09/01 19:10
The Daily Biotech Pulse: Sanofi, Regeneron Drop COVID-19 Study, 2 Positive AstraZeneca Catalysts, Brickell Awarded Japanese Patent
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 12:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACST. Analyze the recent business situations of Acasti Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACST stock price target is 1.122 with a high estimate of 3.003 and a low estimate of 0.1142.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 5.08M
% Owned: 5.24%
Shares Outstanding: 96.89M
TypeInstitutionsShares
Increased
4
978.91K
New
5
225.89K
Decreased
4
134.08K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.56%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Director
Roderick Carter
President/Chief Executive Officer/Director
Janelle D'Alvise
Chief Financial Officer
Brian Ford
Chief Operating Officer
Pierre Lemieux
Vice President
Laurent Harvey
Other
Brian Groch
Secretary/Director
Jean-Daniel Belanger
Director
Jean-Marie Canan
Independent Director
Donald Olds
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACST
Acasti Pharma Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. It is developing a cardiovascular drug, CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia. CaPre is a krill oil derived mixture containing polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). CaPre is designed to reduce triglycerides while also potentially providing beneficial effects on low-density lipoprotein (LDL) cholesterol (LDL-C) and high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with severe hypertriglyceridemia.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Acasti Pharma Inc stock information, including NASDAQ:ACST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACST stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACST stock methods without spending real money on the virtual paper trading platform.